TAG Therapeutics

TAG Therapeutics is a Vienna-based preclinical-stage biotechnology company developing precision medicines for telomere pathologies and age-related disorders. Spun out of the Danube Labs acceleration program, the company's proprietary TELOBLOCK platform utilizes antisense oligonucleotides (ASOs) to target non-coding RNA produced at shortened or damaged telomeres. By selectively inhibiting the telomeric DNA damage response (tDDR), TELOBLOCK counteracts cellular senescence and downstream inflammation without altering telomere length. The company's lead therapeutic focus is Idiopathic Pulmonary Fibrosis (IPF), with additional pipeline programs targeting short telomere syndromes, bone marrow failure, dyskeratosis congenita, and aplastic anemia.